CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, ...
A new highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...
In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for ...
A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.
The first engineered cell therapy has come to the fight against solid tumors. Fox Chase Cancer Center has begun using Tecelra, an FDA-approved treatment for synovial sarcoma.
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...
Jefferson Health oncologist Jennifer Johnson had exhausted all the standard treatment options for her 49-year-old patient with esophageal cancer, who was likely to die within months. Surgery, ...
According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results